Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.39 |
| ▸ | ARG2 | P78540 | 4/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 3/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706524 | 1.00 | TDP1 (0.42) | TDP1CYP4F2CYP4A11ARG2DGAT1 | |
| SCHEMBL27465368 | 0.89 | DGAT1 (0.36) | TDP1CYP4F2CYP4A11ARG2DGAT1 | |
| SCHEMBL2270879 | 0.86 | ODC1 (0.42) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL2270874 | 0.86 | ODC1 (0.42) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL345584 | 0.86 | FDPS (0.36) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL9543424 | 0.86 | FDPS (0.36) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL9016090 | 0.86 | ODC1 (0.42) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL4617700 | 0.84 | ODC1 (0.37) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL4617707 | 0.84 | ODC1 (0.37) | ARG2DGAT1ARG1GGT1MEN1 | |
| SCHEMBL6432480 | 0.84 | DGAT1 (0.33) | ARG2DGAT1ARG1GGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493402-B2 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-1366018-B1 | OMEGA-AMINOALKYLAMIDES OF (R)-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-06 | — | — | EP | disclosed |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | Dompé S.p.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-8288368-B2 | inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | disclosed |
| EP-1366018-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.P.A. (IT) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068377-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.p.A. (IT) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | TDP1 3863/4885CYP4F2 1364/4885CYP4A11 877/4885 |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | C5AR2, C3AR1, C5AR1 | TDP1 2096/4885CYP4F2 1142/4885CYP4A11 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.